GSK 299423
From Self-sufficiency
| GSK 299423 | |
|---|---|
| File:GSK 299423.png | |
| File:GSK299423 3D 2XCS.png | |
| 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C25H27N5O2S |
| Molar mass | 461.58 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
File:GSK 299423 with Staphylococcus aureus DNA gyrase PDB 2XCS.png
Cartoon representation of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB 2xcs.
GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]
No animal studies have been reported. No application has been made for human clinical trials.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />| 50px | This systemic antibacterial-related article is a stub. You can help ssf by expanding it. |
- Jump up ↑ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010
- Jump up ↑ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs'" Daily Finance, August 6, 2010
- Jump up ↑ Bax BD; et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. doi:10.1038/nature09197. (primary source)
